Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
5 participants
INTERVENTIONAL
2019-11-01
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
NCT04752267
18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
NCT01621906
PET Imaging of Intracranial Cancers With 18F-FSPG
NCT02370563
[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
NCT00832598
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
NCT01985971
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with Brain Cancer
Participants with new or suspected recurrent brain tumors
PET/MR with [18F]PARPi
One PET/MR study (with up to 3 scan times) with \[18F\]PARPi
[18F]PARPi
Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET/MR with [18F]PARPi
One PET/MR study (with up to 3 scan times) with \[18F\]PARPi
[18F]PARPi
Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>/= 18 years
* Minimum at least one brain lesion size \>/= 1.5cm diameter
* Scheduled to undergo treatment at MSK
* Willingness to sign informed consent
* Able to receive intravenous gadolinium contrast per MSK Department of Radiology guidelines
Exclusion Criteria
* Pregnancy or breast-feeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Young, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-311
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.